List of Excipients in Branded Drug PROAIR DIGIHALER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Respiratory LLC	PROAIR DIGIHALER	albuterol sulfate	59310-540	LACTOSE MONOHYDRATE

ProAir Digihaler Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

ProAir Digihaler is a digitally enabled dry-powder inhaler containing albuterol sulfate, with lactose monohydrate as the principal disclosed excipient. Its commercial protection depends less on excipient exclusivity than on the combined protection of inhaled-powder performance, device design, dose-counting electronics, software, manufacturing controls, and regulatory equivalence. The strongest opportunities are lactose-carrier optimization, low-cost digital-device substitution, authorized-generic strategies, and differentiated albuterol DPI products that avoid direct replication of Teva’s device architecture.

What excipients are used in ProAir Digihaler?

ProAir Digihaler contains micronized albuterol sulfate blended with lactose monohydrate. The lactose functions primarily as a carrier and bulking agent in the dry-powder formulation.

Attribute	ProAir Digihaler
Active ingredient	Albuterol sulfate
Delivered dose	90 mcg albuterol per actuation
Dosage form	Breath-actuated dry-powder inhaler
Principal disclosed excipient	Lactose monohydrate
Device	Digitally enabled, multidose DPI
Applicant	Teva Pharmaceuticals
FDA application	NDA 212084
FDA approval	2018
Therapeutic category	Short-acting beta-2 adrenergic agonist
Primary use	Treatment or prevention of bronchospasm in patients aged 4 years and older

The product labeling identifies lactose monohydrate as an inactive ingredient and warns that patients with severe milk-protein allergy may be at risk because lactose may contain trace milk proteins.[1] This creates a formulation and labeling constraint for any follow-on product using lactose as a carrier.

The commercial formulation challenge is the very low drug load. A nominal 90-mcg albuterol dose requires uniform distribution of micronized active pharmaceutical ingredient across a substantially larger carrier mass. Product performance depends on particle size, carrier surface morphology, adhesion and detachment forces, blend homogeneity, moisture exposure, and inhalation airflow.

How does lactose function in the ProAir Digihaler formulation?

Lactose monohydrate performs four main functions:

1. It increases the total powder mass to improve dose handling.
2. It acts as a carrier for micronized albuterol sulfate.
3. It supports metering and dose uniformity in a multidose inhaler.
4. It influences aerosolization and fine-particle dose during inhalation.

The most important excipient variables are lactose particle-size distribution, fines content, crystallinity, surface energy, moisture content, and supplier consistency. Small changes can alter the fraction of active drug that detaches from the carrier and reaches the lower respiratory tract.

A generic developer should not treat lactose as an interchangeable commodity. Two lactose grades with the same compendial designation can produce different emitted-dose and fine-particle-dose results because of differences in morphology, fines distribution, residual moisture, and surface defects.

Excipient optimization priorities

Formulation variable	Commercial and regulatory impact
Lactose particle size	Controls carrier surface area and drug detachment
Lactose fines	Can improve aerosolization but may change blend uniformity
Micronized albuterol size	Affects respirable fraction and dose consistency
Moisture content	Can increase agglomeration and reduce emitted dose
Blend order and mixing energy	Affects drug distribution and segregation
Carrier surface treatment	May improve aerosolization but increases formulation complexity
Packaging humidity barrier	Protects dose performance over shelf life
Device resistance	Changes the patient’s delivered dose and airflow profile

The commercial opportunity is strongest where excipient engineering improves performance without introducing a new active ingredient or a materially different clinical profile. A developer may seek lower-cost lactose sourcing, improved moisture control, or a carrier grade that maintains fine-particle dose across a wider range of inhalation efforts.

What formulation patents protect ProAir Digihaler?

The likely protection around ProAir Digihaler is broader than the disclosed excipient list. Key patent categories include:

• Albuterol sulfate dry-powder compositions.
• Carrier-based blends using lactose or related inhalation excipients.
• Dose-metering systems for multidose DPIs.
• Breath-actuated activation.
• Dose-counting and inhalation-event detection.
• Electronic recording and transmission of inhaler use.
• Device sealing and moisture protection.
• Software and data-management functions.
• Manufacturing processes for consistent powder loading.

A lactose-only formulation is difficult to protect broadly because lactose is a conventional inhalation carrier. The defensible claims are more likely to arise from specific particle-size ranges, carrier-to-drug ratios, powder-performance parameters, manufacturing steps, or the interaction between formulation and device.

The highest-value claim scope generally links the powder to a device. A formulation claim may cover a blend with defined aerodynamic performance, while a device claim may require a particular reservoir, airflow path, dose-metering mechanism, sensor arrangement, or electronic architecture. A competing product can reduce infringement risk by changing one or more of those elements while maintaining equivalent clinical performance.

What is the Orange Book status of ProAir Digihaler?

ProAir Digihaler is an FDA-approved prescription drug product under NDA 212084. FDA approval and Orange Book treatment should be analyzed separately from patents covering standalone digital-inhaler technology.

The Orange Book may identify patents submitted for the approved drug product, but not every patent relevant to the commercial product will necessarily appear there. Device, software, manufacturing, and broader platform patents can sit outside the Orange Book-listed set. A complete freedom-to-operate review therefore requires both Orange Book analysis and a broader patent-family search.

The regulatory exclusivity period associated with the 2018 approval is no longer the principal barrier to competition. The more significant barriers are likely patent claims, device sameness, inhalation-equivalence requirements, and the cost of demonstrating reliable performance across the labeled patient population.

What patent expirations matter?

The practical patent timetable is claim-specific. Relevant dates can include:

• Original utility-patent expiration.
• Patent-term adjustment.
• Patent-term extension, if granted.
• Continuation and divisional patent expiration.
• Terminal disclaimers.
• Later-issued device or software patents.
• Pediatric exclusivity, where applicable.
• Litigation-related stays or settlement restrictions.

Patent expiration cannot be inferred from the FDA approval date. A patent filed years before approval can expire earlier than a later-issued continuation patent. A generic or follow-on developer should map each family by earliest priority date, continuation status, terminal disclaimer, PTA, and Orange Book listing.

When does ProAir Digihaler lose exclusivity?

Regulatory exclusivity has already declined in importance because the product was approved in 2018. Patent and device exclusivity can continue beyond the regulatory exclusivity period, depending on the surviving claims.

For business planning, the relevant entry scenarios are:

Entry scenario	Likely pathway	Main barrier
Same active and substantially same DPI	ANDA under section 505(j)	Device sameness and equivalent performance
Albuterol DPI with different device	505(b)(2) NDA	Clinical, device, and human-factors requirements
Non-digital albuterol DPI	ANDA or 505(b)(2) depending on reference and differences	Product-specific equivalence
Digital inhaler with different software	505(b)(2) or combination-product strategy	Software, device, cybersecurity, and clinical validation
Lactose-free or alternative-carrier DPI	505(b)(2) is more likely	New formulation and performance data
Authorized generic	Commercial agreement with NDA holder	Licensing and supply economics

The launch date also depends on Paragraph IV certifications, patent litigation, any 30-month stay, and settlement terms. A company can have a technically approvable product but still face delayed commercialization because the device or formulation patent estate remains active.

Which companies are challenging ProAir Digihaler?

The competitive threat comes from several groups rather than a single direct challenger:

• Generic inhaler manufacturers with albuterol DPI capabilities.
• Established respiratory companies with multidose DPI platforms.
• Device manufacturers offering low-cost electronic dose counters.
• Digital-health companies seeking connected inhaler partnerships.
• Contract development and manufacturing organizations with inhalation-powder expertise.
• Manufacturers of non-digital albuterol DPIs that compete for the same patient and prescriber segment.

The most direct competitive substitute is ProAir RespiClick, another Teva albuterol DPI that uses a breath-actuated format without the same level of digital functionality. Albuterol HFA products, including generic albuterol sulfate inhalation aerosols, remain a major commercial alternative and create price pressure on any albuterol DPI.

What commercial opportunities exist in ProAir Digihaler excipients?

1. Lower-cost lactose sourcing

A developer can qualify multiple lactose suppliers and optimize grade selection for dose uniformity, fine-particle dose, and stability. The opportunity is most attractive if the existing supply chain uses a premium inhalation-grade lactose that can be replaced with a validated equivalent.

The value is not limited to ingredient cost. Better supply diversification can reduce manufacturing interruptions and improve negotiating leverage. Supplier changes require comparability work because carrier attributes directly affect aerosol performance.

2. Carrier engineering

Modified lactose systems may improve drug detachment and respirable dose. Potential approaches include:

• Controlled lactose fines fractions.
• Engineered carrier morphology.
• Surface-modified lactose.
• Alternative sugar carriers.
• Low-moisture formulations.
• Carrier blends that reduce segregation.

The patent risk rises when the carrier is combined with defined aerodynamic outcomes or specific device conditions. The commercial case is strongest when the formulation delivers equivalent or better performance at lower manufacturing cost.

3. Lactose-free positioning

A lactose-free albuterol DPI could address patients with severe milk-protein allergy and create a clinically differentiated product. Potential carriers include mannitol, trehalose, leucine-containing systems, or engineered excipient particles.

This strategy creates new development costs. The developer must establish powder flow, emitted dose, aerodynamic particle-size distribution, moisture stability, and tolerability. The product may require a 505(b)(2) pathway if the formulation and device differ materially from the reference product.

4. Moisture-resistant packaging

A major opportunity is packaging rather than a new excipient. High-barrier blister systems, desiccant integration, improved device sealing, and low-moisture manufacturing can protect aerosol performance during storage.

A robust moisture-control strategy can reduce product losses, support longer shelf life, and improve performance in humid markets. It can also create process and packaging patent opportunities without relying on a new active pharmaceutical ingredient.

5. Digital-device cost reduction

The electronic system adds cost that is not necessary for bronchodilator delivery. A competing product could use a simpler dose counter, smartphone connectivity, or an optional digital accessory rather than embedding equivalent electronics in every inhaler.

The commercial tradeoff is clear:

Product model	Advantage	Risk
Fully integrated digital DPI	Strong adherence and usage data	Higher manufacturing cost
Basic breath-actuated DPI	Lower cost and simpler regulatory package	Less differentiation
DPI with passive dose counter	Moderate cost and usability	Limited data value
Disposable inhaler plus reusable sensor	Lower recurring electronics cost	Device integration complexity
Connected smartphone accessory	Flexible software model	Lower patient engagement

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are not the purchase of lactose or albuterol sulfate. They are:

• Micronization of albuterol sulfate to a consistent respirable size.
• Uniform low-dose blending.
• Control of segregation during filling and transport.
• Moisture control.
• Device filling accuracy.
• Reproducible emitted dose.
• Fine-particle-dose consistency across inhalation flow rates.
• Assembly of the device and electronic components.
• Human-factors validation.
• Stability testing under long-term and accelerated conditions.

A formulation that performs well in laboratory cascade-impactor testing can still fail during scale-up. Blend residence time, hopper geometry, vibration, filling speed, and packaging conditions can change dose uniformity.

Intellectual-property risk is highest where the product combines a defined powder blend with a particular inhaler mechanism. A design-around analysis should separate:

1. Active pharmaceutical ingredient claims.
2. Excipient and particle-engineering claims.
3. Device claims.
4. Sensor and electronics claims.
5. Software claims.
6. Manufacturing-process claims.
7. Packaging and moisture-control claims.

How does ProAir Digihaler compare with competing albuterol products?

Product category	Active ingredient	Device	Digital functionality	Commercial position
ProAir Digihaler	Albuterol sulfate	Breath-actuated DPI	Integrated	Premium digital DPI
ProAir RespiClick	Albuterol sulfate	Breath-actuated DPI	Limited or absent	Direct non-digital DPI substitute
ProAir HFA and generics	Albuterol sulfate	Pressurized metered-dose inhaler	Absent	Low-cost, established standard
Other albuterol inhalers	Albuterol sulfate	MDI or DPI	Varies	Broad generic competition

ProAir Digihaler has greater differentiation than a conventional albuterol product, but its digital functionality also increases cost and regulatory complexity. The product must justify the premium through adherence support, usage monitoring, payer acceptance, or a channel-specific value proposition.

What revenue exposure and launch opportunities exist?

Revenue exposure is concentrated in the albuterol rescue-inhaler market, where payer and pharmacy substitution can rapidly compress prices. A generic or follow-on product should prioritize:

• Low-cost manufacturing.
• Broad pharmacy distribution.
• Device familiarity.
• Reliable performance at low inspiratory flow.
• Simple patient instructions.
• Payer coverage.
• Interchangeability or substitutability where available.

A direct digital copy may face a narrow premium market. A better commercial opportunity may be a lower-cost albuterol DPI using a validated lactose system and a simplified device, followed by a separate connected version for health systems, asthma programs, or employer-sponsored adherence initiatives.

Key Takeaways

• ProAir Digihaler uses albuterol sulfate with lactose monohydrate as the principal disclosed excipient.
• Lactose is a carrier and dose-performance component, not merely an inactive filler.
• The strongest formulation opportunities involve carrier engineering, moisture control, lactose-free alternatives, and supplier diversification.
• Patent risk extends beyond the Orange Book to device, electronics, software, packaging, and manufacturing patents.
• A direct generic DPI may require substantial device and inhalation-equivalence work.
• A 505(b)(2) strategy may be more practical for a materially different device, carrier, or digital architecture.
• The most attractive commercial strategy may be a lower-cost non-digital DPI or a modular connected inhaler rather than a direct digital replica.
• Generic albuterol HFA products remain the principal price benchmark and limit premium pricing.

FAQs

Is lactose monohydrate essential to ProAir Digihaler performance?

No. Lactose is the disclosed carrier, but alternative excipients may be possible if they produce equivalent dose uniformity, aerosolization, stability, and tolerability.

Can a company launch a lactose-free generic albuterol DPI?

Potentially, but a materially different carrier may require a 505(b)(2) approach rather than a conventional ANDA, depending on the reference product and FDA equivalence requirements.

Does an Orange Book patent cover all ProAir Digihaler technology?

No. Orange Book patents do not necessarily capture every device, software, manufacturing, or platform patent relevant to the product.

Is ProAir Digihaler more defensible than ProAir RespiClick?

The digital device creates more potential claim categories, but it also provides more design-around opportunities. Defensibility depends on the surviving patent claims, not on the presence of electronics alone.

What is the highest-value excipient opportunity?

The strongest near-term opportunity is carrier and moisture optimization that reduces cost while preserving emitted dose and fine-particle performance. A lactose-free formulation offers greater differentiation but carries higher development and regulatory risk.

References

1. U.S. Food and Drug Administration. (2018). ProAir Digihaler: Prescribing information. Teva Respiratory, LLC.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: ProAir Digihaler, NDA 212084. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda

4. U.S. Food and Drug Administration. (2009). Metered dose inhaler and dry powder inhaler drug products: Chemistry, manufacturing, and controls documentation. Guidance for industry.

5. United States Pharmacopeia. (2024). General chapter <601>: Inhalation and nasal drug products: Aerosols, sprays, and powders. United States Pharmacopeial Convention.

6. European Medicines Agency. (2009). Guideline on the pharmaceutical quality of inhalation and nasal products. EMA/CHMP/QWP/49313/2005 Corr.

7. U.S. Food and Drug Administration. (2022). Considerations for the development of dry powder inhalers. FDA inhalation product guidance materials.